Results 111 to 120 of about 808,538 (334)

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

open access: yes, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Merck KGAA v. Integra Lifesciences I, Ltd.: Greater Research Protection for Drug Manufacturers [PDF]

open access: yes, 2006
Merck sought protection under a statutory exemption from claims of patent infringement brought by Integra Lifesciences. The Court held unanimously that the safe harbor contained in 35 U.S.C.
Rubin, Samuel
core   +1 more source

Comparative effectiveness and safety of image guidance systems in neurosurgery: a preclinical randomized study [PDF]

open access: bronze, 2015
Hani J. Marcus   +7 more
openalex   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

open access: yesMolecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller   +17 more
wiley   +1 more source

Supplementary Tables 1 - 3 from Improved Statistical Modeling of Tumor Growth and Treatment Effect in Preclinical Animal Studies with Highly Heterogeneous Responses <i>In Vivo</i>

open access: gold, 2023
Teemu D. Laajala   +9 more
openalex   +1 more source

TREX1, a predator for treating MSI‐H tumors?

open access: yesMolecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya   +2 more
wiley   +1 more source

Racotumomab: An Anti-Idiotype Vaccine Related to N-Glycolyl-Containing-Gangliosides. Preclinical and Clinical Data.

open access: yesFrontiers in Oncology, 2012
Neu-glycolyl (NeuGc) containing gangliosides are attractive targets for immunotherapy with anti-idiotype mAbs, because these glycolipids are not normal components of the cytoplasmatic membrane in humans, but their expression has been demonstrated in ...
Ana María eVázquez   +7 more
doaj   +1 more source

Data from Masitinib Antagonizes ATP-Binding Cassette Subfamily C Member 10–Mediated Paclitaxel Resistance: A Preclinical Study

open access: gold, 2023
Rishil J. Kathawala   +9 more
openalex   +1 more source

Home - About - Disclaimer - Privacy